Fig. 5.
Comparison of vascular proliferation (immunostaining of CD31)
Vascular ingrowth (200×) at baseline (A) and after the three-week treatment period (B) visibly increased, denoted with black arrow at the vessel. Immunostaining of CD31 (C) significantly enhanced post-treatment (sample size of each group, n=15; a)P<0.05, Wilcoxon signed-rank test). Pre, pre-treatment; Post, post-treatment.